Skip to main content
. 2017 Nov 17;46(1):242–255. doi: 10.1093/nar/gkx1147

Figure 4.

Figure 4.

Pol β-depleted cells are sensitive to BLM and NU7441 and KU0060648. (A) MCF7-Pol β-depleted cells are sensitive to BLM. (B) U2OS-Pol β-depleted cells are sensitive to BLM. (C) MCF7-Pol β-depleted cells are sensitive to DNA-PKcs inhibitor NU7441. (D) U2OS-Pol β-depleted cells are sensitive to DNA-PKcs inhibitor NU7441. (E) MCF7-Pol β-depleted cells are sensitive to DNA-PKcs inhibitor KU0060648. (F) MCF7-Pol β-depleted cells are more sensitive to BLM when pre-treated with DNAPKcs inhibitor. Pol β-depleted MCF7 cells were pre-treated with 10 μM DNA-PKcs inhibitor for 24 h. Cells were then treated with a range of concentrations of 10, 50, 100 and 250 μg/ml BLM for 24 h. (G) U2OS-Pol β-depleted cells are more sensitive to BLM when pre-treated with DNA-PKcs inhibitor. Pol β-depleted U2OS cells were pre-treated with 10 μM DNA-PKcs inhibitor for 24 h. Cells were then treated with a range of concentrations of 10, 50, 100, 250, 500 and 1000 μg/ml BLM for 24 h. * (P = 0.05).